(CercleFinance.com) – Ionis Pharmaceuticals announced on Wednesday that eplontersen, the treatment for familial amyloid polyneuropathy it is developing with AstraZeneca, has met its primary endpoint in phase 3 clinical trials.
The American biopharmaceutical group indicates that the drug provided a “statistically significant and clinically satisfactory” improvement in patients with transthyretin amyloid neuropathy (NAH-TTR) compared to a placebo.
These results – presented at a scientific congress in Heidelberg (Germany) – showed an 81.2% reduction in the level of transthyretin in patients who received treatment.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
